

Systemic Therapy Update

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New BCCA Website
- **Cancer Drug Manual** – Revised: Enzalutamide, Doxorubicin, Oxaliplatin, Pegaspargase, BCCA Hazardous Drug List
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UGIPGEMABR
Revised: UBRAVERIB, UBRAVKAD, UBRAVPTRAD, CNTEMOZMD, GIAVPG, GICART, GICPART, GIGAJCC, GIGAJCPT, GIGAVCCT, GIGAVECC, GIGECC, UGIOCTLAR, UGIPGEMABR, GIRCRT, UGUPRAD, HNOTTSH, LYABVD, LYPALL
- **Provincial Systemic Therapy Program**: Vinca Alkaloids Preparation Policy Typo Corrected
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW BCCA WEBSITE

This will be launched in April. The new website comes with a new design that should be easier to read and navigate. It is more mobile-friendly for smartphones and tablets.

Best viewed on modern browsers

The new website is best viewed on Google Chrome or Internet Explorer (version 8 or higher). To check what browser is on your computer, visit <https://whatbrowser.org/>.

Key differences

The website has a new design and a change to the overall layout. Information for health professionals is still in a section titled Health Professionals (www.bccancer.bc.ca/health-professionals). Key information for patients and families will be found in one of two sections: Our Services (www.bccancer.bc.ca/our-services) and Health Info (www.bccancer.bc.ca/health-info).

Website address (URL)

The website URL remains as www.bccancer.bc.ca. However, most sections will have new URLs as the overall website structure will have changed. Bookmarks and favourites will need to be updated once the new website is live. To import existing bookmarks or favourites from Internet Explorer into Chrome:

1. In the top-right corner of the browser window, click the Chrome menu.
2. Select Bookmarks > Import Bookmarks and Settings.
3. Select the program that contains the bookmarks that you want to import.
4. Click Import.
5. Click Done.

EDITOR'S CHOICE

Where the imported bookmarks will appear:

- If you have not created any bookmarks in Chrome, the bookmarks will import directly into the bookmarks bar, normally docked underneath the address bar.
- If you already have bookmarks in Chrome, the bookmarks will import into a new folder labelled "Imported from Internet Explorer". You can see your bookmarks by clicking the Chrome menu and selecting Bookmarks.

More details about the new website are available at: www.bccancer.bc.ca/ABCCA/WebsiteUpgrade.

CANCER DRUG MANUAL

HIGHLIGHTS OF REVISED MONOGRAPHS AND HANDOUTS

Enzalutamide: The auxiliary label cautioning patients to avoid alcohol is no longer needed. Alcohol intake may increase the risk for seizures in patients taking enzalutamide. However, the risk for seizures may also be increased with abrupt alcohol withdrawal in patients who regularly drink large amounts. The Enzalutamide Patient Handout directs patients concerned about their alcohol consumption to discuss further with their physician.

Other changes

- *Doxorubicin*: intravesical administration added under Parenteral Administration
- *Oxaliplatin*: calcium and magnesium infusion for neurotoxicity is no longer recommended
- *Pegaspargase (also known as PEG-asparaginase)*: the vial supply and stability information has been updated

CHANGES TO BCCA HAZARDOUS DRUG LIST

The BCCA Hazardous Drug List has been revised in response to the update by the US National Institute for Occupational Safety and Health (NIOSH) in September 2014 (www.cdc.gov/niosh/docs/2014-138). NIOSH has reviewed 42 new drugs or existing drugs with new blackbox warnings between January 2010 to December 2011. Some highlights of the changes include:

<i>Reclassified as hazardous</i>	<i>Reclassified as non-hazardous</i>	<i>Newly classified as hazardous*</i>
Dexrazoxane Erlotinib	Aldesleukin Asparaginase Bevacizumab Nilutamide Pegaspargase	Abiraterone Brentuximab Cabazitaxel Crizotinib Eribulin Trastuzumab emtansine Vandetanib Vemurafenib

* These drugs were already classified as hazardous through BCCA evaluation

CANCER DRUG MANUAL

The BCCA Hazardous Drug List has also been reformatted, with a single list containing BCCA benefit drugs and drugs used via the BCCA Compassionate Access Program (CAP). This replaces the previous separate NIOSH list and the BCCA Addendum. The process for the evaluation of hazardous drugs remains unchanged.

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UGIPGEMABR	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PAclitaxel-Nab (ABRAXANE®) and Gemcitabine

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UBRAVERIB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Serum creatinine clarified under Test</i>	Palliative Therapy for Metastatic Breast Cancer using Eribulin
UBRAVKAD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Monitoring for cardiac function clarified</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA®)
UBRAVPTRAD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Monitoring for cardiac function clarified</i>	Palliative Therapy for Metastatic Breast Cancer Using Pertuzumab, Trastuzumab (HERCEPTIN), and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer
CNTEMOZMD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Therapy for Malignant Brain Tumours Using Metronomic Dosing of Temozolomide
GIAVPG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration clarified</i>	First-line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and CISplatin
GICART	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dosing schedule clarified</i>	Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy
GICPART	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dosing schedule clarified</i>	Combined Modality Therapy for Carcinoma of the Anal Canal using CISplatin, Capecitabine and Radiation Therapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GIGAJCC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dose in renal dysfunction clarified</i> <i>capecitabine dose in renal dysfunction clarified</i>	Adjuvant Chemotherapy of Gastric Cancer patients with D2 Resection (node negative) or ineligible for adjuvant chemoradiation, using CISplatin and Capecitabine
GIGAJCPR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Premedications clarified,</i> <i>Precautions for cardiac toxicity updated,</i> <i>capecitabine dose in renal dysfunction clarified</i>	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy
GIGAVCCT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dose in renal dysfunction clarified</i>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Using CISplatin, Capecitabine and Trastuzumab (HERCEPTIN)
GIGAVECC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dose in renal dysfunction clarified</i>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, CISplatin and Capecitabine
GIGECC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dose in renal dysfunction clarified</i>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, CISplatin and Capecitabine
UGIOCTLAR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Initiation of treatment clarified</i>	Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumours of the GI Tract Using Octreotide (SANDOSTATIN LAR)
UGIPGEMABR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>IV administration bag and tubing clarified</i>	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel-Nab (ABRAXANE®) and Gemcitabine
GIRCRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine dosing schedule clarified</i>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
UGUPRAD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Albumin added to baseline tests</i>	Therapy for Metastatic Castration Resistant Prostate Cancer Using Radium-223
HNOTTSH	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Intramuscular administration clarified</i>	Radioiodine Imaging and Treatment in Patients with Thyroid Cancer Using Thyrotropin Alpha
LYABVD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Bleomycin infusion time clarified</i>	Treatment of Hodgkin's disease with DOXOrubicin, Bleomycin, vinBLASTine and Dacarbazine
LYPALL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected,</i> <i>Treatment table reformatted</i>	Lymphoma Palliative Chemotherapy

PROVINCIAL SYSTEMIC THERAPY PROGRAM

POLICY ON VINCA ALKALOID PREPARATIONS (POLICY V-40)

A small typo has been corrected. In the statement “All Vinca Alkaloids should....be given *within* 5-15 minutes...”, should read “...given *over* 5-15 minutes...”.

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 Victoria Kletas, MSc (Clin Pharm)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN
 Rob Watt, BSc (Pharm)